{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-241943","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2023-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.333002+00:00","generated_at":"2026-06-10T08:48:29.209982+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Taysha doses second Rett syndrome patient with TSHA-102 in REVEAL Phase 1/2 adult trial","bullets":["Second adult patient dosed with TSHA-102 in REVEAL Phase 1/2 adult trial for Rett syndrome in Canada.","Clinical data from both low-dose adult patients to be reported on mid-November earnings call after IDMC review.","Enrollment completion in low-dose cohort (third patient) expected Q4 2023.","First pediatric patient dosing expected Q1 2024; FDA cleared pediatric IND.","UK MHRA CTA for pediatric patients submitted; feedback expected H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-241943","json":"https://secwatch.observer/filing/0001193125-23-241943.json","markdown":"https://secwatch.observer/filing/0001193125-23-241943.md","text":"https://secwatch.observer/filing/0001193125-23-241943.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523241943/0001193125-23-241943-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523241943/d529272d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T08:48:29.209982+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}